Gilead Sciences closing two cardiovascular-focused research and development offices in Colorado. The closures stem from Gilead’s acquisition of California-based CV Therapeutics, according to an Associated Press report. A spokesperson for Gilead said the company is consolidating its operations in California.
AstraZeneca partnered with Forest Laboratories for the development and commercialization of ceftaroline, an experimental antibiotic. The partnership includes markets outside of the US, Canada and Japan. Financial terms of the deal were not disclosed.
